A discussion on the promising findings from the TOPCAT study.
John McMurray, MBChB: One of the large trials conducted in patients with HFpEF [heart failure with preserved ejection fraction] was the TOPCAT trial, which enrolled just under 3500 patients with heart failure and an ejection fraction of 45% or above. That trial compared spironolactone, a mineralocorticoid receptor antagonist or aldosterone antagonist, to placebo, and the overall result of the trial was not significant. In other words, there was not a significant reduction in the primary composite end point, although there was a nominally significant reduction in heart failure hospitalization of around 15%.
The TOPCAT trial was an interesting trial because it was conducted in the [United States], Canada, Brazil, and Argentina, as well as in Russia and Georgia. As it turned out, the patients who were enrolled in Russia and Georgia perhaps didn’t have heart failure and maybe didn’t take their spironolactone, so they had a very low event rate, and there was no difference between spironolactone and placebo. In fact, I won’t go into all the detail, but there is good evidence that both of those things I said are correct. Therefore, if you look at just the patients enrolled in North America and South America, then the trial would be positive, there would be a benefit to spironolactone.
Interestingly, the US Food and Drug Administration is having an advisory committee in December, and on one of the 2 days of that advisory committee, they will be reviewing the TOPCAT trial data to see whether there might be an indication for spironolactone in patients with heart failure with preserved ejection fraction, or at least for some of those patients. This is because, like sacubitril/valsartan and like candesartan, the benefit seems to be largest in patients with an ejection fraction in the lower end of the range of ejection fraction that was included in the trial.
Top 5 Most-Read Heart Failure Articles of 2024
December 23rd 2024Some of the top heart failure research looked at statins and semaglutide for heart failure with preserved ejection fraction, diabetes-related heart failure risks, and the protective cardiovascular effects of COVID-19 vaccination.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Intermountain Healthcare and Story Health Partner to Optimize Rural Heart Failure Care
February 7th 2023On this episode of Managed Care Cast, we speak with Tom Stanis, CEO and cofounder of Story Health, and Phillip Wood, Intermountain Ventures program director, on how their partnership came about, how it is going so far, and the future of their collaboration.
Listen